Chung-Tsen Hsueh

Research & Grantsmanship 

  Funded Research Project (PI)

• Southwest Oncology Group institutional principal investigator for Loma Linda University Cancer Center. 06/01/10 – 3/6/14.   ( 6/2010 - 4/2020 )

• A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without HyperaAcute® - Pancreatic cancer Vaccine in Subjects with Surgically Resected Pancreatic Cancer ( 10/2010 - 12/2011 ) Link...

• Phase I Safety and Pharmacokinetic Study of XRP6258 (Cabazitaxel) in Advanced Solid Tumor Patients with Varying Degrees of Hepatic Impairment ( 10/2010 - 12/2011 ) Link...

• A randomized, double-blind, multi-center phase III study of brivanib plus best supportive care  (BSC) versus placebo plus BSC in subjects with advanced hepatocellular carcinoma who have failed or are intolerant to sorafenib ( 2/2010 - 12/2011 ) Link...

• A multinational, randomized, double-blind study, comparing the efficacy of aflibercept once every 2 weeks versus placebo in patients with metastatic colorectal cancer treated with irinotecan / 5-FU combination (FOLFIRI) after failure of an oxaliplatin based regimen ( 12/2009 - 12/2011 ) Link...

• Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients with Advanced Gallbladder Carcinoma or Cholangiocarcinoma ( 5/2010 - 7/2011 )

• A Phase I Study of Azacitidine in  Combination with Cisplatin in Patients with Recurrent or Metastatic Non-small Cell Lung Cancer or Squamous Cell Carcinoma of the Head and Neck ( 3/2009 - 12/2010 ) Link...

• A Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients With Metastatic Carcinoid Tumors Whose Disease-Related Symptoms Are Inadequately Controlled by Somatostatin Analogues ( 11/2008 - 12/2010 ) Link...

• An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer ( 10/2008 - 12/2010 ) Link...

• An Open label single arm trial investigating zalutumumab, a Human Monoclonal Anti-EGF receptor Antibody, in combination with Best Supportive Care, in Patients with Non-Curable Squamous Cell Carcinoma of the Head and Neck who have Failed Standard Platinum-based Chemotherapy ( 8/2008 - 12/2010 ) Link...

• A Randomized Phase 2 Study of 7 on/7 off Capecitabine in Combination with Bevacizumab and Either Short-course Irinotecan or Short-course Oxaliplatin as First-Line Treatment for Patients with Metastatic Colorectal Cancer aka The X-BIO Study ( 8/2008 - 12/2010 ) Link...

• A Phase 1b/2 Study of AMG 655 in Combination with Modified FOLFOX6 and Bevacizumab for the First-Line Treatment of Subjects with Metastatic Colorectal Cancer ( 8/2008 - 12/2010 ) Link...

• Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) with or without Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX or XELOX ( 2/2008 - 12/2010 ) Link...

• A Randomized Phase III Trial of Oxaliplatin Plus 5-Fluorouracil/Leucovorin with or without Cetuximab after Curative Resection for Patients with Stage III Colon Cancer ( 2/2008 - 12/2010 ) Link...

• A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with or without Oxaliplatin with Preoperative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil with or without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum ( 10/2007 - 8/2010 ) Link...

  Funded Research Project (CI)

• A phase II trial of gemcitabine and erlotinib plus proton-chemotherapy and CapOx for locally advanced pancreatic cancer ( 0/2012 - 0/2015 )

• A phase I/II trial of stereotactic body proton therapy for patients with liver metastases ( 0/2012 - 0/2015 )

• A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers ( 10/2007 - 2/2011 ) Link...